Bicara Therapeutics Inc.

BCAX

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0002023658

SEC filings (opens in a new tab)

In the last 90 days, Bicara Therapeutics Inc. insiders filed 0 open-market purchases and 7 sales; 171 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.

Q4 2025 vs. Q3 2025

How the institutions holding Bicara Therapeutics Inc. changed between Q3 2025 and Q4 2025.

All holders in Q4 2025 All holders in Q3 2025

13F holders of BCAX: Q3 2025 compared with Q4 2025
Measure	Q3 2025	Of which not filed for Q4 2025	Q4 2025	Change
Holders	114	1	140	+27
Shares	50.2M	292	57.1M	+6.89M (+13.7%)
Value	$792.5M	$4.61K	$960.7M	+$168.2M (+21.2%)

1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (44)

Institutions that held Bicara Therapeutics Inc. at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to BCAX in Q4 2025
Institution	Shares	Value	% of portfolio
Janus Henderson Group PLC	2,646,285	$44.5M	0.02%
Franklin Resources Inc	1,620,025	$27.3M	0.01%
Citadel Advisors LLC	772,258	$13.0M	0.01%
Ensign Peak Advisors, Inc	401,444	$6.76M	0.01%
Palo Alto Investors LP	298,575	$5.03M	0.70%
OrbiMed Advisors LLC	209,100	$3.52M	0.07%
Hudson Bay Capital Management LP	150,000	$2.52M	0.01%
D. E. Shaw & Co., Inc.	136,522	$2.30M	0.00%
Soleus Capital Management, L.P.	100,000	$1.68M	0.07%
Jane Street Group, LLC	85,583	$1.44M	0.00%
Shay Capital LLC	64,300	$1.08M	0.17%
Y-Intercept (Hong Kong) Ltd	59,937	$1.01M	0.02%
Rafferty Asset Management, LLC	59,819	$1.01M	0.00%
HRT Financial LP	50,147	$843.0K	0.00%
Norges Bank	42,889	$721.8K	0.00%
Dimensional Fund Advisors LP	40,934	$688.9K	0.00%
Dark Forest Capital Management LP	37,636	$633.4K	0.03%
Swiss National Bank	32,300	$543.6K	0.00%
Susquehanna International Group, LLP	30,693	$516.6K	0.00%
Caption Management, LLC	23,000	$387.1K	0.02%
Profund Advisors LLC	22,177	$373.2K	0.01%
Jump Financial, LLC	20,988	$353.2K	0.00%
Voya Investment Management LLC	18,195	$306.2K	0.00%
Group One Trading, L.P.	16,914	$284.7K	0.01%
VARCOV Co.	15,653	$263.4K	0.10%
Brevan Howard Capital Management LP	14,117	$237.6K	0.00%
Graham Capital Management, L.P.	13,116	$220.7K	0.01%
Letko, Brosseau & Associates Inc	11,175	$188.1K	0.00%
Aquatic Capital Management LLC	11,127	$187.3K	0.01%
SG Americas Securities, LLC	11,122	$187.0K	0.00%
China Universal Asset Management Co., Ltd.	8,927	$150.2K	0.01%
KLP Kapitalforvaltning AS	3,500	$58.9K	0.00%
Mirae Asset Global Investments Co., Ltd.	2,662	$44.8K	0.00%
GF Fund Management Co. Ltd.	1,076	$18.1K	0.00%
Smartleaf Asset Management LLC	274	$4.42K	0.00%
Daiwa Securities Group Inc.	182	$3.00K	0.00%
Rockefeller Capital Management L.P.	121	$2.04K	0.00%
UBS Asset Management Americas Inc	76	$1.28K	0.00%
Bellevue Asset Management, LLC	61	$1.03K	0.00%
MAI Capital Management	45	$758	0.00%
WPG Advisers, LLC	26	$438	0.00%
Comerica Bank	12	$202	0.00%
Stone House Investment Management, LLC	10	$168	0.00%
Aster Capital Management (DIFC) Ltd	1	$17	0.00%

Sold out (17)

Institutions that held Bicara Therapeutics Inc. at the end of Q3 2025 and filed for Q4 2025 without it.

Institutions that sold out of BCAX in Q4 2025
Institution	Shares, Q3 2025	Value, Q3 2025
Blackstone Group Inc.	1,224,336	$19.3M
Schonfeld Strategic Advisors LLC	504,085	$7.96M
Sectoral Asset Management Inc	266,495	$4.21M
Silverarc Capital Management, LLC	250,606	$3.96M
Superstring Capital Management LP	175,902	$2.78M
Schroder Investment Management Group	173,651	$2.41M
Marshall Wace, LLP	112,086	$1.77M
Cantor Fitzgerald, L. P.	100,000	$1.58M
Sphera Funds Management Ltd.	85,747	$1.35M
Raymond James Financial Inc	67,701	$1.07M
ExodusPoint Capital Management, LP	53,882	$850.8K
Cinctive Capital Management LP	41,849	$660.8K
Point72 Asset Management, L.P.	30,138	$475.9K
Jain Global LLC	26,179	$413.4K
Caxton Corp	10,941	$172.8K
Federated Hermes, Inc.	667	$10.5K
SBI Securities Co., Ltd.	1	$16

Not filed for Q4 2025 yet (1)

Institutions that held Bicara Therapeutics Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding BCAX in Q3 2025 that haven't filed for Q4 2025
Institution	Shares, Q3 2025	Value, Q3 2025
Point72 Europe (London) LLP	292	$4.61K